Royal London Asset Management Ltd. Decreases Stock Holdings in argenx SE (NASDAQ:ARGX)

Royal London Asset Management Ltd. lessened its holdings in argenx SE (NASDAQ:ARGX) by 3.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 31,737 shares of the company’s stock after selling 1,201 shares during the period. Royal London Asset Management Ltd.’s holdings in argenx were worth $19,518,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of ARGX. Whipplewood Advisors LLC purchased a new stake in shares of argenx in the fourth quarter valued at about $37,000. Global Retirement Partners LLC lifted its holdings in shares of argenx by 369.2% in the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock valued at $38,000 after purchasing an additional 48 shares in the last quarter. Jones Financial Companies Lllp lifted its holdings in shares of argenx by 1,016.7% in the fourth quarter. Jones Financial Companies Lllp now owns 67 shares of the company’s stock valued at $41,000 after purchasing an additional 61 shares in the last quarter. Farther Finance Advisors LLC lifted its holdings in shares of argenx by 38.2% in the fourth quarter. Farther Finance Advisors LLC now owns 76 shares of the company’s stock valued at $47,000 after purchasing an additional 21 shares in the last quarter. Finally, Venturi Wealth Management LLC purchased a new stake in shares of argenx in the fourth quarter valued at about $66,000. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenx Stock Up 0.3 %

argenx stock opened at $615.02 on Friday. argenx SE has a 52-week low of $352.77 and a 52-week high of $678.21. The firm has a fifty day moving average of $634.69 and a 200-day moving average of $599.15. The firm has a market capitalization of $37.37 billion, a P/E ratio of -698.89 and a beta of 0.59.

argenx (NASDAQ:ARGX) last announced its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The business had revenue of $761.22 million during the quarter, compared to the consensus estimate of $678.52 million. On average, research analysts expect that argenx SE will post 3.13 EPS for the current fiscal year.

Analysts Set New Price Targets

ARGX has been the topic of several recent research reports. William Blair reaffirmed an “outperform” rating on shares of argenx in a report on Friday, February 28th. Piper Sandler boosted their price objective on shares of argenx from $620.00 to $725.00 and gave the company an “overweight” rating in a research report on Tuesday, January 7th. Sanford C. Bernstein raised shares of argenx from a “market perform” rating to an “outperform” rating in a research report on Monday, March 17th. Wedbush reissued an “outperform” rating and issued a $655.00 price objective on shares of argenx in a research report on Tuesday, December 3rd. Finally, HC Wainwright boosted their price objective on shares of argenx from $717.00 to $720.00 and gave the company a “buy” rating in a research report on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, argenx has a consensus rating of “Moderate Buy” and an average price target of $687.00.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.